What is OS Therapies's proceeds from warrant exercises?

OS Therapies (OSTX) reported proceeds from warrant exercises of $722.22K in Q1 2025.

What does proceeds from warrant exercises mean?

The cash proceeds generated when holders of warrants exercise their right to purchase common stock at a predetermined price. This serves as a non-dilutive or secondary source of capital that indicates investor confidence in the company's long-term equity value.

OS Therapies OSTX Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

AMB

Ambiq Micro, Inc.AMBQ

$3.01M—

XTI Aerospace, Inc.XTIA

$7.44M+743,800%

Shattuck Labs, Inc.STTK

$5.44M—

TRV

Trevi Therapeutics, Inc.TRVI

$2.54M—

Dakota GoldDC

$10.9M+572%

AvePoint, Inc.AVPT

$0-100%

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's proceeds from warrant exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's proceeds from warrant exercises?: OS Therapies (OSTX) reported proceeds from warrant exercises of $722.22K in Q1 2025.
What does proceeds from warrant exercises mean?: The cash proceeds generated when holders of warrants exercise their right to purchase common stock at a predetermined price. This serves as a non-dilutive or secondary source of capital that indicates investor confidence in the company's long-term equity value.